



Additional Supplemental Materials

Supplemental Figure 1. Progression Free and Overall Survival by Mutation Type

A. Progression Free Survival by Mutation Type



B. Overall Survival by Mutation Type



Supplemental Figure 1. Progression-free and overall survival by mutation type.

A. – B. Kaplan-Meier curves for progression-free and overall survival by mutation type, comparing the subgroup of 32 OC patients with “definitely somatic” HRR mutations compared to the 174 with “definitely germline” HRR mutations. Germline mutation carriers had a significantly increased hazard of both progression (HR 1.59, 95% CI 1.01 – 2.51, $p = 0.045$) and death (HR 2.32, 95% CI 1.18 – 4.58, $p = 0.01$) when compared to those with somatic mutations. Hazard ratios were adjusted for study treatment, age, size of residual tumor, stage of disease, initial performance status, and mutation type.

Supplemental Table 2. Mutations by source of sequenced DNA

Source of DNA		DNA from Blood (Germline) N = 788			
			DNA from Tumor (Germline and Somatic) N = 731		
		Blood Only (Germline)	**Blood and Tumor (Somatic)	Tumor Only (Germline and Somatic)	All Sources
N (%)		464 (38.8)	324 (27.1)	407 (34.0)	1195 (100)
Mutation Group	<i>BRCA1</i> (%)	78 (10.0)*	17 (5.2)	53 (13.0)	148 (12.4)
	<i>BRCA2</i> (%)	46 (5.8)*	7 (2.2)	25 (6.1)	78 (6.5)
	Other HRR (%)	50 (6.3)*	8 (2.5)	23 (5.7)	81 (6.8)
	Total HRR (%)	174 (22.1)*	32 (9.9)	101 (24.8)	307 (25.7)

*Percentages calculated out of the total 788 patients with germline testing

**Subset of patients who had negative germline testing, therefore only somatic mutations detected